Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.


Journal

Acta cardiologica
ISSN: 1784-973X
Titre abrégé: Acta Cardiol
Pays: England
ID NLM: 0370570

Informations de publication

Date de publication:
Nov 2022
Historique:
pubmed: 28 9 2021
medline: 13 1 2023
entrez: 27 9 2021
Statut: ppublish

Résumé

Cardiac amyloidosis (CA) is often overlooked or misdiagnosed. Effects of growing disease awareness, diagnostic ameliorations and novel treatment options on CA diagnosis and management are scarcely reported. To report trends in diagnosis, referral routes, clinical presentation, early onset diagnostic red flags and outcome in de novo CA subjects. An unselected cohort of 139 de novo CA patients over an 8-year period in a tertiary referral hospital was recruited. Transthyretin (ATTR, 82%, Although CA diagnostic uptake and referral improve, specialist-specific disease and diagnostic red flag ignorance result in non-timely diagnosis and unfavourable outcome.

Sections du résumé

BACKGROUND UNASSIGNED
Cardiac amyloidosis (CA) is often overlooked or misdiagnosed. Effects of growing disease awareness, diagnostic ameliorations and novel treatment options on CA diagnosis and management are scarcely reported.
OBJECTIVE UNASSIGNED
To report trends in diagnosis, referral routes, clinical presentation, early onset diagnostic red flags and outcome in de novo CA subjects.
METHODS UNASSIGNED
An unselected cohort of 139 de novo CA patients over an 8-year period in a tertiary referral hospital was recruited.
RESULTS UNASSIGNED
Transthyretin (ATTR, 82%,
CONCLUSIONS UNASSIGNED
Although CA diagnostic uptake and referral improve, specialist-specific disease and diagnostic red flag ignorance result in non-timely diagnosis and unfavourable outcome.

Identifiants

pubmed: 34565298
doi: 10.1080/00015385.2021.1976450
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

791-804

Auteurs

Philippe Debonnaire (P)

Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Mathias Claeys (M)

Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.
Department of Cardiology, University Hospital Leuven, Belgium.

Maarten De Smet (M)

Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.
Department of Cardiology, University Hospital Ghent, Belgium.

Sander Trenson (S)

Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Michelle Lycke (M)

Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Catherine Demeester (C)

Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Jan Van Droogenbroeck (J)

Department of Haematology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

An S De Vriese (AS)

Department of Nephrology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Kristof Verhoeven (K)

Department of Neurology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Nikolaas Vantomme (N)

Department of Neurosurgery, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Jan Van Meirhaeghe (J)

Department of Orthopaedic surgery, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Barbara Willandt (B)

Department of Gastroenterology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Margareta Lambert (M)

Department of Geriatry, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Pascale de Paepe (P)

Departments of Pathology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Joost Delanote (J)

Departments of Radiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Frank De Geeter (F)

Departments of Nuclear Medicine, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Rene Tavernier (R)

Departments of Cardiology, Bruges Amyloidosis Centre, Sint-Jan Hospital Bruges, Bruges, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH